
Re: Co-author review required for TOPMed T2D Paper proposal 1229!

Jennifer Brody <jeco@uw.edu>
To: Alisa Manning <amanning@broadinstitute.org>
Cc: "Wessel, Jennifer" <wesselj@iu.edu>

Thu, Nov 12, 2020 at 3:10 PM

Hi Alisa,

I am submitting Nov 17th, as I usually give co-authors at least a week to review, then it will be 1-2 weeks for an expedited P&P review. Does that timeline work since you have Bruce's approval for the TOPMed submission? If not, let me know and I'll see what I can do.

-Jen

On Nov 12, 2020, at 12:04 PM, Alisa Manning <amanning@broadinstitute.org> wrote:

Hi Jen --

Can you confirm that the paper has been sent out to the CHS P&P? What is the typical time frame for a response? Is there any way that we could request expedited review?

Thanks!

Alisa

On Tue, Nov 10, 2020 at 7:28 PM Jennifer Brody <jeco@uw.edu> wrote:

Hi Alisa,

Here are the authorship details:

Susan R. Heckbert
Cardiovascular Health Research Unit, University of WA
Department of Epidemiology, University of WA

James S. Floyd
Cardiovascular Health Research Unit, University of Washington
Department of Medicine, University of Washington
Department of Epidemiology, University of Washington

No personal acknowledgments and no disclosures for either.

Thanks!

On Nov 10, 2020, at 1:00 PM, Alisa Manning <amanning@broadinstitute.org> wrote:

Sure thing. Can you forward this for their review and ask that they send us the appropriate affiliations, acknowledgements and disclosures?

Thanks!

Alisa

On Tue, Nov 10, 2020 at 3:00 PM Jennifer Brody <jeco@uw.edu> wrote:

Hi Alisa, All,

It appears that only Bruce and I are listed for CHS on the paper, as I'm assuming Nick is representing HVH. We would like to invite James Floyd who oversaw the phenotype creation for this project and Susan Heckbert. Would that be possible?

Thanks, Jen

On Nov 9, 2020, at 9:56 AM, Alisa Manning
<amanning@broadinstitute.org> wrote:

Hi Bruce and the rest of the CHS team --

Thanks for the time spent on our paper draft.

I had included Russ as his name was listed in some compiled information from TOPMed regarding each study's review process. I didn't cross-check PIs against our author list. I apologize for the confusion and appreciate Bruce's guidance on the correct process: having the CHS authors to review and approve and subsequent submission to the CHS P&P.

Thanks again everyone.
Alisa Manning

On Mon, Nov 9, 2020 at 12:03 PM Bruce M Psaty <psaty@uw.edu> wrote:

Dear All,

Lovely paper. I have one comment and found two typos. Is weak transcription in islets adequate evidence to "demonstrate islet-specificity"? The answer is above my pay grade.

In the abstract, use "functional characterization" rather than "function characterization." In the introduction, use "but studies have been limited to ..."

Please add the new contract number for CHS acknowledgement: 75N92021D00006. Thanks.

Once all CHS authors approve, we can submit. I will ask Jen to do so. (Let us know if that is not possible.) I suspect that approval will arrive in plenty of time.

Thanks for the opportunity to participate.

Bruce

=====

Bruce M. Psaty, MD, PhD
Professor, Medicine & Epidemiology
University of Washington
Cardiovascular Health Research Unit

1730 Minor Avenue, Suite #1360

Seattle, WA 98101-1466

Phone: 206/221-7775

Fax: 206/221-2662

Email: psaty@uw.edu

=====

From: Alisa Manning [mailto:amanning@broadinstitute.org]

Sent: Saturday, November 07, 2020 6:08 PM

To: Bruce M Psaty; Russell Tracy; Jennifer Brody; Nicholas L. Smith

Cc: Alisa Manning; Wessel, Jennifer; Gaynor, Sheila Marie; Dicorpo, Daniel, Anthony; Meigs, James B.,M.D.; Dupuis, Josee

Subject: Re: Co-author review required for TOPMed T2D Paper proposal 1229!

Dear Jen, Russell, Nicholas and Bruce –

I am writing to request expedited review of our manuscript by the CHS cohort, as we have a funding requirement that we meet a November 30th deadline for manuscript submission.

We understand that CHS has a checklist of requirements that need to be verified by a CHS cohort representative. We can send additional details as needed.

Please let us know if you have any questions or concerns, or if you anticipate a delay in the cohort approval process.

Many thanks,

Alisa

On Sat, Nov 7, 2020 at 9:00 PM Alisa Manning
<amanning@broadinstitute.org> wrote:

Hello co-authors!

We are sending you the penultimate manuscript “*Whole genome sequence analysis for fasting glucose and fasting insulin levels in diverse cohorts from the NHLBI TOPMed Program*” from the TOPMed T2D Working Group. We plan to submit this to the American Journal of Human Genetics as a (short format) Report.

To meet a fiscal grant deadline of **November 30th** we are requesting your ***quick*** responses:

1. **Co-authors:** respond to us that you approve the manuscript in **by Wednesday, November 11th**.
 - a. Please check your affiliations and acknowledgments
2. **Study/PI of study:** submit to P&P committees or respond to us that as Study PI you approve manuscript immediately so we can document where it is in the approval pipeline (we have to document this for submission to TOPMed P&P before we receive approval to submit to journal)
3. **Comments on manuscript:** send comments **by Monday, November 16th** (Earlier if possible, please)

Main Text: https://www.dropbox.com/s/7diwyzlaq4lr9gk/TOPMed.FG.FI.7NOV2020_for_cohort_review_clean.pdf?dl=0

Supplementary Text: https://www.dropbox.com/s/nn74zyp8027n8k0/TOPMed.FG.FI.Suppl.Note.7NOV2020_clean.pdf?dl=0

Supplementary Tables: https://www.dropbox.com/s/6qncowxin5lc01c/SupplementaryTables.7NOV2020_clean.xlsx?dl=0

Best,

Alisa Manning, Jennifer Wessel, Dan DiCorpo, Sheila Gaynor, James Meigs and Josée Dupuis